Telogen Effluvium: Diagnosis and Treatment Guide

Clinical Overview

Telogen effluvium (TE) is a non-scarring alopecia characterized by diffuse hair shedding resulting from premature synchronization of hair follicles into the telogen (resting) phase. Unlike androgenetic alopecia which causes permanent miniaturization, or alopecia areata with inflammatory destruction, telogen effluvium is fundamentally reversible—hair regrowth occurs as follicles exit the telogen phase and re-enter anagen. This condition accounts for 8-17% of hair loss complaints in dermatology clinics and affects women more frequently than men, likely due to hormonal sensitivity and higher healthcare-seeking behavior.

Epidemiology

Telogen effluvium affects approximately 8-17% of dermatology patients presenting with hair loss, with female predominance (60-70% of cases). The condition can occur at any age but most commonly affects women aged 30-60 years. Peak incidence correlates with major life stressors or systemic illness. Acute telogen effluvium (onset within 3 months of triggering event) resolves within 3-6 months in most cases. Chronic telogen effluvium (lasting >6 months) affects 25-50% of patients who initially present with acute TE, creating substantial psychosocial morbidity despite the condition's fundamentally benign nature.

Pathophysiology

Hair follicles cycle through three phases: anagen (growth, 2-6 years), catagen (transition, 2-3 weeks), and telogen (resting, 2-3 months). Normally, approximately 85-90% of scalp hair is in anagen while 10-15% is in telogen. Telogen effluvium results from stress-induced synchronization of follicles into telogen phase—up to 30-70% of scalp hair simultaneously enters telogen. The pathophysiology involves catecholamine and cortisol elevation during stress, which suppress growth factors (IGF-1, HGF) and growth factor signaling in follicle stem cells, prematurely terminating anagen and forcing entry into catagen-telogen. The mechanism is reversible: once the triggering stress is removed or resolved, follicles resume normal cycling and re-enter anagen, producing new hair growth 3-6 months later as telogen hairs are shed and replaced by anagen hairs.

Triggering Factors

Acute telogen effluvium is typically preceded by a specific trigger occurring 2-4 months before hair shedding onset (the latency between anagen termination and telogen shedding). Common triggers include: fever from acute illness (influenza, COVID-19, bacterial infections); severe emotional stress (bereavement, divorce, financial crisis, major life changes); major surgery or general anesthesia; significant weight loss or crash dieting (often 20+ lbs over 2-3 months); medications (beta-blockers, anticonvulsants, anticoagulants, ACE inhibitors, NSAIDs); hormonal changes (oral contraceptive initiation or discontinuation, postpartum period, menopause); thyroid dysfunction; iron deficiency; vitamin B12 or folate deficiency; and chronic systemic illness (lupus, HIV/AIDS, malignancy).

Clinical Features

Patients report sudden-onset increased hair shedding—often 50-200 more hairs daily than baseline—noticed during shampooing, combing, or when touching scalp. Hair comes out painlessly in clumps. Despite dramatic shedding, patients typically do not develop visible baldness; diffuse thinning may be apparent to the patient or family but scalp is not visibly bald. The pull test may yield 6-10 or more telogen hairs (normal is fewer than 6). Importantly, scalp is not inflamed, tender, or symptomatic. Nails may show transverse grooves (Beau's lines) corresponding to the time of stress, reflecting concurrent disruption of nail matrix growth. Patients report anxiety about hair loss, fearing progression to pattern baldness or permanent alopecia, though reassurance regarding the condition's benign and self-limited nature substantially reduces psychologic morbidity.

Diagnosis

Diagnosis is primarily clinical, based on history of recent stressor and diffuse shedding pattern. The pull test showing >6 telogen hairs supports diagnosis. Dermoscopy reveals predominantly telogen hairs (club-shaped roots without inner root sheath) intermixed with anagen hairs. Trichogram—analysis of plucked hairs under microscopy—shows elevated telogen percentage (>20-30%). Scalp biopsy is rarely needed unless diagnosis is uncertain. Importantly, investigating for treatable underlying causes is essential: thyroid function tests (TSH, free T4), complete blood count (for anemia), iron studies (ferritin, serum iron, TIBC), vitamin B12 and folate levels, comprehensive metabolic panel (assessing kidney and liver function), and ANA screening (for lupus) if systemic symptoms are present. Women should be asked about medication changes, recent pregnancies, hormonal changes, and weight loss. Many cases of chronic telogen effluvium represent occult deficiency states or undiagnosed systemic illness rather than primary psychological stress.

Acute vs. Chronic Telogen Effluvium

Acute telogen effluvium is defined as onset of shedding within 3 months of clear triggering event with expected resolution within 3-6 months once the trigger is removed. Recovery is typically complete with full restoration of baseline hair density. Chronic telogen effluvium (lasting >6 months) affects approximately 25-50% of initially-acute cases and represents either: (1) identification of new or ongoing triggers that perpetuate the condition, (2) underlying deficiency states (iron, vitamin B12, protein) that persist unrecognized, (3) occult systemic illness (thyroid disease, lupus, malignancy), or (4) primary chronic telogen effluvium of unclear etiology. Chronic cases may continue indefinitely, creating sustained psychologic distress. Unlike acute TE with predictable resolution, chronic TE may require extended treatment and investigation.

Management

Management of acute telogen effluvium is primarily reassurance and identification of triggering factors. Patients benefit from clear explanation that telogen effluvium is benign, reversible, and self-limited (typically resolving within 3-6 months). This reassurance alone reduces anxiety substantially. Identifying and addressing treatable triggers is essential: if iron deficiency is present, iron supplementation (ferrous sulfate 325 mg daily with vitamin C for enhanced absorption) should be provided; if thyroid dysfunction is found, appropriate replacement or antithyroid therapy is initiated; if B12 deficiency exists, supplementation (1000 mcg IM monthly or 1000-2000 mcg daily oral) is provided; if medications are culpable, alternative agents without this side effect should be considered if possible.

For chronic telogen effluvium, several therapeutic options are employed. Topical minoxidil 2-5% solution applied twice daily to the scalp may provide modest benefit by stimulating anagen and potentially accelerating follicle re-entry into growth phase; response rates are 30-40% in chronic TE. Nutritional support including biotin supplementation (2.5 mg daily), zinc supplementation (15-25 mg daily if deficient), and adequate dietary protein (1.2-1.5 g/kg body weight) support hair growth. Stress reduction techniques (meditation, yoga, cognitive behavioral therapy) address psychological components. Low-dose systemic corticosteroids (prednisone 0.5-1 mg/kg daily for 2-4 weeks with taper) are sometimes used for severe acute TE though evidence is limited. Hair care counseling emphasizing gentle handling, minimizing chemical treatments, and reducing heat styling protects remaining hair from mechanical damage.

Prognosis

Acute telogen effluvium has excellent prognosis: 50-70% of patients experience complete hair regrowth within 3-6 months, and 90% achieve complete recovery by 12 months. Patients rarely progress to androgenetic alopecia or permanent hair loss from telogen effluvium alone. Chronic telogen effluvium has more variable prognosis depending on whether underlying causes are identified and treated: if iron, B12, or thyroid deficiency is corrected, 60-70% achieve stabilization or improvement. If no treatable cause is identified, 40-50% continue chronic shedding despite treatment, though true baldness development is rare. The key to favorable outcome is identifying modifiable triggers and correcting deficiency states rather than attributing all cases to psychological stress.

When to See a Dermatologist

Seek dermatology evaluation if experiencing rapid-onset diffuse hair shedding, particularly if accompanied by systemic symptoms (fatigue, weight changes, temperature intolerance, skin changes). Dermatologists can confirm diagnosis, initiate appropriate investigation for underlying causes, and provide reassurance regarding the condition's benign nature. Red flags warranting urgent evaluation include shedding accompanied by scalp inflammation, focal patches of alopecia (suggesting alopecia areata rather than TE), or progressive hair loss despite treatment (suggesting misdiagnosis).

Frequently Asked Questions

Will I go completely bald from telogen effluvium? No. Telogen effluvium causes diffuse thinning but not permanent baldness. Even in severe cases, scalp does not become visibly bald. Hair regrows completely once the triggering factor is resolved, typically within 3-6 months.

How long does telogen effluvium last? Acute telogen effluvium typically lasts 3-6 months from onset of shedding. Recovery is usually complete by 6-12 months. Chronic telogen effluvium (lasting >6 months) may persist for years but still carries favorable prognosis if underlying causes are addressed.

Can stress alone cause prolonged hair loss? Acute psychological stress typically triggers telogen effluvium lasting 3-6 months. If hair loss persists beyond 6 months, investigation for iron deficiency, thyroid disease, nutritional deficiencies, or other systemic illness is warranted rather than attributing ongoing loss purely to stress.

Should I take supplements for telogen effluvium? Iron, biotin, and zinc supplementation may provide modest benefit, particularly if deficiencies exist. However, supplementation without documented deficiency shows limited efficacy. Correction of underlying deficiencies (confirmed by testing) is more important than empiric supplementation.

References